Independent Director 2025 Annual Performance Report
To all shareholders and shareholder representatives:
As an independent director of Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Zhongsheng Pharma"), I have diligently performed my duties in accordance with the Company Law, the Administrative Measures for Independent Directors of Listed Companies, the Articles of Association, and the Independent Director Work System during my term. I actively attended relevant meetings, carefully reviewed all proposals submitted to the Board of Directors, and fully exercised my role as an independent director to safeguard the overall interests of the Company and the legitimate rights and interests of all shareholders, especially small and medium shareholders.
Herein is my report on the performance of my duties as an independent director during my term in 2025:
I. Basic Information
(I) Work Experience, Professional Background, and Concurrent Positions
I am Mou Xiaorong, holding a Master's degree, and I am a Certified Public Accountant and a Certified Tax Agent. I am currently a teacher, associate professor, and master's supervisor at the School of Management, South China Agricultural University. I also serve as an independent director for Guangzhou Kangsheng Biotechnology Co., Ltd. and Guangdong Yuanshang Logistics Co., Ltd., and as a director for Guangzhou Henglong Intelligent Equipment Co., Ltd. I served as an independent director of the Eighth Board of Directors of Zhongsheng Pharma from December 2022 to December 2025.
I meet the qualification requirements for independent directors of listed companies as stipulated by relevant laws, regulations, and regulatory rules, and have been filed and reviewed by the Shenzhen Stock Exchange.
(II) No Circumstances Affecting Independence
During my tenure as an independent director of Zhongsheng Pharma, I have complied with the requirements of the Administrative Measures for Independent Directors of Listed Companies, the Shenzhen Stock Exchange Main Board Listed Company Self-Regulatory Management Guide No. 1 – Standardized Operation of Main Board Listed Companies, the Articles of Association, and the Independent Director Work System regarding independence. I have conducted an independence self-assessment in accordance with regulatory rules, and the results have been submitted to the Board of Directors. The Board of Directors has evaluated my independence and found no circumstances that may affect my independent and objective judgment. I have no relationship with the Company and its controlling shareholder that may hinder independent and objective judgment. I perform my duties independently, free from the influence of the Company's controlling shareholder or any other entity or individual with a conflict of interest, and there are no circumstances that affect the independence of independent directors.
II. Overview of Annual Performance
(I) Attendance at Meetings
In 2025, during my term of office, I have maintained a diligent and responsible work attitude, attending Board of Directors and special committee meetings on time, actively participating in board decision-making, and expressing clear opinions on the matters discussed. There were no instances where I failed to attend in person twice consecutively or delegated another independent director to attend on my behalf.
- Attendance at Board of Directors and Shareholders' Meetings
During 2025, the Company's Board of Directors held 12 meetings, reviewing and approving 46 proposals. I was scheduled to attend 12 Board meetings and actually attended all 12, with 2 attended in person and 10 via communication methods. There were no instances of delegation or absence.
During 2025, the Company convened 5 general meetings of shareholders, reviewing and approving 19 proposals. I attended 4 general meetings of shareholders.
- Attendance at Board Special Committee Meetings